AXSM Stock Analysis: Buy, Sell, or Hold?
AXSM - Axsome Therapeutics, Inc
$205.40
-2.37 (-1.14%)
▼
5d:
-5.03%
30d:
-14.77%
90d:
-12.96%
HOLD
MODERATE Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Get Alerted When AXSM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AXSM shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: AXSM shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$176.34
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$109.49
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AXSM is currently trading at $205.40, which is considered oversold relative to its 30-day fair value range of $210.26 to $233.27. From a valuation perspective, the stock is trading at a discount (Forward PE: 40.8) compared to its historical average (80.2). Remarkably, the market is currently pricing in an annual earnings decline of 20.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, AXSM is in a uptrend. The price is currently testing key support at $205.09. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AXSM scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $285.42 (+39.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AXSM is in a uptrend. The price is currently testing key support at $205.09. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AXSM scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $285.42 (+39.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$210.26 -
$233.27
Company Quality Score
55/100
(HOLD)
Options IV Signal
30th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
59.6%
Protect Your Profits
Holding AXSM? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 30th percentile)
- BEARISH: Weak technical setup (37/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 39.0% below Wall St target ($285.42)
- CAUTION: 5-day price weakness (-5.0%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$210.26 -
$233.27
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$12.21
(5.9%)
Support & Resistance Levels
Support Level
$205.09
Resistance Level
$223.05
Current Trend
Uptrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
40.80
Wall Street Target
$285.42
(+39.0%)
Revenue Growth (YoY)
45.5%
Profit Margin
-24.7%
Valuation Discount vs History
-20.2% cheaper
PE vs Historical
40.8 vs 80.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-20.2%
(market-implied from PE analysis)
1-Year Target
$184.86
(-10%)
2-Year Target
$166.37
(-19%)
3-Year Target
$149.74
(-27%)
3-Yr Target (if PE normalizes)
(PE: 41→80)
$294.32
(+43%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 40.8 to 80.2
Stabilization Target:
$403.73
(+96.6%)
PE Expansion Potential:
+96.6%
Share & Embed Analysis
Last updated: August 24, 2026 6:24 PM ET
Data refreshes hourly during market hours. Next update: 7:24 PM
Data refreshes hourly during market hours. Next update: 7:24 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AXSM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Ari Maizel
SELL
7500 shares
2026-04-22
Mark Coleman
SELL
25000 shares
2026-02-26
Mark L Jacobson
SELL
35378 shares
2026-02-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 65 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 34 SELL |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 39 SELL |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 41 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 42 HOLD |
Advanced AXSM Option Strategies
Professional options setups generated by AI based on today's AXSM price and gamma walls.
